17-N-Allylamino-17-Demethoxygeldanamycin Induces a Diverse Response in Human Acute Myelogenous Cells
The goal of this study was to ascertain the specific effects of 17-N-Allylamino-17-demethoxygeldanamycin (17-AAG) treatment in human acute myelogenous leukemia (AML). Four human leukemia cell lines were treated with varying doses of 17-AAG followed by analysis of toxicity, apoptosis, proliferation, and cell cycle. Cell cycle analysis revealed that the cells accumulate in G2/M phase within 96 hours of treatment, although the effect was not equivalent among the cell lines. p21, p53 expression and MDR1 activity were among the possible mechanisms uncovered for the differing responses. Exploiting these differences may allow for more effective combinatory treatments in patients with AML.
Napper, N., Sollars V., 17-N-Allylamino-17- demethoxygeldanamycin induces a diverse response in human acute myelogenous cells (2010). Leukemia Research 34(11), 1493-1500. doi:10.1016/j.leukres.2010.05.024